Letter to Editor, J Pharm Drug Deliv Res Vol: 7 Issue: 1
Recombinant Human Insulin- PLGA NP Administered Orally after Combination with a Protease Inhibitor (N-Ethylmaleimide) in vivo Results
Abdelkader DH1,2*, El-Gizawyb SA2, Faheemc AM3, McCarrona PA1and OsmanbK MA2
1School of Pharmacy and Pharmaceutical Sciences, Saad Centre for Pharmacy and Diabetes, Ulster University, Cromore Road, Coleraine, Co. Londonderry, BT52 1SA, UK
2Faculty of Pharmacy, Pharmaceutical Technology Department, Tanta University, Tanta, 31111, Egypt
3Sunderland Pharmacy School, University of Sunderland, Sunderland, SR1 3SD, UK
*Corresponding Author : Dalia H. Abdelkader, MSc
Pharmaceutical Technology Department, University of Tanta, Tanta, 31111, Egypt
Tel: +2 (040) 3336007-3336409
Fax: +2 (040) 3335466
E-mail: mhdalia86@gmail.com
Received: May 02, 2018 Accepted: May 16, 2018 Published: May 23, 2018
Citation: Abdelkader DH, El-Gizawyb SA, Faheemc AM, McCarrona PA, Osmanb MA (2018) Recombinant Human Insulin-PLGA NP Administered Orally after Combination with a Protease Inhibitor (N-Ethylmaleimide): in vivo Results. J Pharm Drug Deliv Res 7:2. doi: 10.4172/2325-9604.1000176
Abstract
Based on our published results, insulin PLGA NP composed from human insulin (5 mg) encapsulated in PLGA 2.5% (w/v) mixed with PEG (2 kDa, 5% w/w) and the external aqueous phase contained 1.25% of PVA (%w/v) were prepared by the modified double emulsion solvent evaporation technique [1,2]. The resulting NP have been investigated for oral administration of recombinant human insulin (100 IU/kg) in diabetic rats [3]. Our animal model, Male Sprague–Dawley rats (12-week-old, obtained from National researches center, Cairo, Egypt.) weighing 250-300 gm were fasted for 6 hours prior to the induction of type I diabetes via i.p injection of streptozotocin (50-60 mg.kg-1, pH=4.5). Rats with blood glucose levels >250 mg dl-1 were considered to be in a diabetic state. Three percent sodium bicarbonate solution (500 μL) in phosphate buffer saline (PBS) was administered through an oral gavage to neutralize gastric acid, a protease inhibitor -PI-(NEthylmaleimide, 2 mM) was physically mixed with free insulin or insulin PLGA-NP before oral administration [4,5]. To investigate the effect of PI, other two animal groups of rats were utilized for free insulin and insulin PLGA-NP without PI (Figure 1) [6,7].